||EPS - Basic
||Market Cap (m)
yes good news, now here comes the but, we need contracts, sales generating deals. awards are on thing, only when we sell the products will the share price move north.|
|the shuffle man: Spekky nice to see you bringing some sunshine to the share price. Maybe news is coming soon.|
|the shuffle man: "A signed agreement by March 2008 with a significant commercial partner for the launch of a mass market product"
Now that would get the share price moving|
|the shuffle man: "Toumaz has conducted clinical testing of the vital-signs monitor chip, but the patch "still needs to go through the safety check," Burdett says. A commercial launch date has not yet been set."
The share price will motor once we get confirmation of the safety checks and a date for the commercial launch. Hopefully this will not be too far away.|
these are all great but whats gonna move the share price forward.......buyers, and where are they??|
looks like CVS are in need of some cash pronto, share price on the floor, investors that were willing to invest large stakes have fled the nest. my worry is why????? lets hope SAAD pick up the slack.|
|the drewster: Cash position remains absolutely key here, they have previously stated that they will need to raise funds ... so from who, and at what price, will be the guiding factor in the next few months share price movement.
All imho, and what do I know?!|
|the shuffle man: at last some publicity
Edited by Robert Watts, Sunday Telegraph
Last Updated: 11:35pm GMT 18/11/2006
Like many smaller AIM-listed investment vehicles, Nanoscience is playing a high stakes poker game where a real result from just one of its venture-backed biotechnology subsidiaries could send its share price soaring.
Nanoscience listed on Aim last March, and is trading at 8.50p, from a high of around 17p last year.
However, experts are particularly impressed by the potential for one of its investments Imperial College spin-out Toumaz Technology Limited, which is developing a revolutionary vital signs monitoring system for patients.
If tests in the first quarter of next year are successful, Toumaz will produce a battery-powered vital signs monitor, so tiny patients will be able to wear it in a bandage or plaster, that will continuously transmit back to doctors for five days.
Nanoscience paid £17.1m for Toumaz, raising an additional £7.1m in development funding, helping to push it to a pre-tax loss of £2.5m in the six months to 29th September. The AIM vehicle has made a series of other acquisitions including a 2.9 per cent stake in Swedish gas sensing development company Applied Sensor Sweden.
Presenting its interim results the company promised a "period of continuing and rapid evolution towards commercialisation". Buy.|
Nanoscience share price data is direct from the London Stock Exchange